Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

GEIGER JESSE J

Troendle August J.

BURWIG SUSAN E

Brady Kevin M.

A class action securities fraud lawsuit has been filed against Medpace Holdings for allegedly making materially false statements about its financial performance. The company missed its book-to-bill ratio guidance of 1.15, reporting only 1.04 due to record backlog cancellations. The stock fell 15.9% on February 10, 2026, following the disclosure. Investors who purchased shares between April 22, 2025 and February 9, 2026 can file a lead plaintiff motion by June 8, 2026.

Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Rosen Law Firm is reminding investors in Lufax Holding Ltd, Medpace Holdings Inc., and Vital Farms Inc. of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false statements, lacked adequate internal controls, and had materially misstated financial results. Investors with losses exceeding $100K are encouraged to seek counsel before the May 20, 2026 deadline.

LU DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Lufax Holding Ltd Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action First Filed by the Firm - LU

Rosen Law Firm is soliciting investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 to join a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, which were described as 'well behaved' when they were actually problematic, leading to investors suffering damages when the true details became public.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Pinterest (PINS), New Era Energy & Digital (NUAI), Gossamer Bio (GOSS), and Medpace Holdings (MEDP). The lawsuits allege that defendants made false or misleading statements regarding business operations, financial performance, and prospects. Investors have until late May to early June 2026 to file lead plaintiff motions.

DEADLINE ALERT for PINS, NUAI, GOSS, MEDP: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Levi & Korsinsky, LLP announces a securities fraud class action lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP) for allegedly concealing backlog cancellation problems and misrepresenting book-to-bill ratios. Investors who purchased MEDP securities between April 22, 2025 and February 9, 2026 can seek lead plaintiff appointment by June 8, 2026. The stock declined over 15.9% ($84.30 per share) after the alleged misconduct surfaced.

MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Defendants Allegedly Violated Securities Disclosure Laws: Levi & Korsinsky

Trading & Investing Education 
Inventor : Ripster Cloud System  
Founder: Tenet Trade Group
https://t.co/0qpaN2fM0W
 https://t.co/GP2vE0fon3

Ripster

Equity Analyst researching high-quality companies at Best Anchor Stocks and Invirtiendo en Calidad. 

Spanish account: @InvEnCalidad

Medpace Holdings Inc (MEDP) Stock Price, Analysis & Trade Signals